Hermetica Superfood Encyclopedia
Legacy index-continuity record: the score and narrative are provisional and must not be represented as validated or human-approved.
Review flags: AWAITING_SEMANTIC_VALIDATION
Bifidobacterium longum SP 07/3 is a clinically studied probiotic strain that produces short-chain fatty acids and antimicrobial compounds to maintain gut microbiome balance. This strain specifically enhances immune function by stimulating immunoglobulin production and reducing pathogenic bacterial populations by up to 60%.
Reported Benefits (Provisional)
Origin & History
Bifidobacterium longum SP 07/3 is a probiotic strain found in the human gastrointestinal tract. It is recognized for its role in maintaining gut health.
Research Narrative (Provisional)
Studies indicate its potential in improving gut health and mental well-being, but more research is needed to confirm these benefits.
Preparation & Dosage
Dosage guidance is withheld because the publication gate has not recorded adequate support for this profile.
Nutritional Profile
- Contains beneficial probiotics. - Enhances gut microbiota diversity. - Supports overall digestive health.
Reported Mechanism (Provisional)
Bifidobacterium longum SP 07/3 colonizes the intestinal tract and produces short-chain fatty acids (acetate, butyrate) that lower intestinal pH, creating an unfavorable environment for pathogenic bacteria. The strain stimulates Toll-like receptors on intestinal epithelial cells, triggering cytokine production and enhancing mucosal immunity. Additionally, it produces antimicrobial peptides and competes for adhesion sites with harmful microorganisms.
Clinical Narrative (Provisional)
Clinical studies have demonstrated that Bifidobacterium longum SP 07/3 supplementation significantly reduces harmful bacterial populations by approximately 60% while improving overall digestive efficiency. Research shows increased immunoglobulin production in subjects taking this strain, indicating enhanced immune system function. Preliminary studies suggest potential benefits for irritable bowel syndrome symptoms, though larger randomized controlled trials are needed to confirm therapeutic efficacy. Most clinical evidence comes from small-scale studies with 4-8 week intervention periods.
Also Known As
Research updates — and 25% off your first order
Join our list for source-aware wellness education, review-state updates, and product news — and unlock 25% off your first Hermetica order. Educational content is not medical advice. No spam, unsubscribe anytime.